

# United States Patent [19]

Loesche

[11] Patent Number: **4,568,535**

[45] Date of Patent: **Feb. 4, 1986**

[54] **COMPOSITION FOR PERIODONTAL  
ADMINISTRATION**

[76] Inventor: **Walter J. Loesche**, 1814 Hermitage,  
Ann Arbor, Mich. 48104

[21] Appl. No.: **631,542**

[22] Filed: **Jul. 16, 1984**

**Related U.S. Application Data**

[63] Continuation-in-part of Ser. No. 405,790, Aug. 6, 1982,  
abandoned.

[51] Int. Cl.<sup>4</sup> ..... **A61K 9/22; A61K 9/52**

[52] U.S. Cl. .... **424/19; 514/365;**  
424/28

[58] Field of Search ..... 424/22, 26, 28, 19,  
424/273 R, 52; 106/35; 514/365

[56] **References Cited  
PUBLICATIONS**

Soskolne et al., New Sustained Release Dosage Form of  
Chlorhexidine for Dental Use, *J. Perio, Res.*,  
18:330-336.

*Primary Examiner*—Johnnie R. Brown



*Assistant Examiner*—C. Joseph Faraci

[57] **ABSTRACT**

A composition for periodontal administration and a  
method of periodontal treatment involving a slow re-  
lease device which can be placed directly into the peri-  
odontal pocket where metronidazole, with or without  
antioxidants, are released over periods of days to weeks  
at a cidal concentration for anaerobes in the domain of  
the periodontal pocket.

**2 Claims, 3 Drawing Figures**

FIG. I



POCKET DEPTH ----- X=8  
GINGIVA TO CEJ ----- Y=3  
ATTACHMENT DISTANCE - Z=5

FIG. 2

PROFILE OF THREE TEETH SHOWING POCKET DEPTH AS DISTANCE BETWEEN GINGIVAL MARGIN 23 AND BONE LEVEL 26. NOTE DEEP POCKETS ( 6 TO 8 MM IN DEPTH ) ARE ABOUT THE FIRST AND SECOND MOLARS ( TEETH 21 AND 22 ).





FIG. 3

PROFILE OF THREE TEETH SHOWING TWO CONTOURED DRUG RELEASE FILMS SUBGINGIVALLY PLACED ONLY IN THOSE SITES WHERE THE POCKET IS 6 MM OR MORE. NOTE THAT THE FILMS CAN BE PLACED OVER THE BIFURCATION SITES 25.



## COMPOSITION FOR PERIODONTAL ADMINISTRATION

### CROSS-REFERENCES

This is a continuation-in-part of Ser. No. 405,790 filed 8/6/82 now abandoned.

### BACKGROUND OF THE INVENTION

#### 1. Technical Field

This invention relates to a composition for periodontal administration that is ideal for anaerobes in the domain of the periodontal pocket and to a novel method of treatment of anaerobic infections in periodontal disease that is dependent upon the slow release of metronidazole from a plastic film that is placed within the periodontal pocket, and which film resides in such pocket for a period of days to weeks.

#### 2. Description of Prior Art

The main cause of tooth loss in adults is periodontal disease. Yet, surprisingly, less than one percent of the public expenditures for dental treatment is for periodontal disease (see *J. Dent. Educ.* 43:320, (1979)). This is because conventional periodontal treatment is too expensive for most individuals, mainly due to the labor intensive, symptomatic treatment that is usually performed by highly skilled specialists.

Periodontal disease is an all-inclusive term for a variety of clinical entities that are forms of either gingivitis or periodontitis. Gingivitis is an inflammation of the gingiva or gums that can be associated with poor oral hygiene and/or hormonal states of the host. It is assumed, but not proven in the human, that gingivitis will progress to a periodontitis, which is the form of the disease in which the infection has progressed to involve the oral tissues which retain the teeth in the jaw bone. Periodontitis is the more severe form of the disease, and if untreated, will eventuate in the loss of the tooth.

Dentists have long assumed that periodontal disease originates by the overgrowth of bacteria on the tooth surfaces in aggregates known as dental plaque. If this plaque persists for long periods of time on the tooth surfaces, it may in some instances calcify, forming the hard substance known as calculus. Numerous studies describe chemical agents which can in vitro and in vivo reduce plaque formation and calculus. However, none of these chemical agents has been reported to be successful in treating periodontitis.

A substantial number of different types of compounds and compositions have been developed for use as antibacterial and antiplaque agents, e.g., benzethonium chloride and cetyl pyridinium chloride, disclosed in U.S. Pat. No. 4,110,429, or as anticalculus agents, e.g., 2-phosphono-butane 1,2,4-tricarboxylic acid, disclosed in U.S. Pat. No. 4,224,308. These compounds are designed to be used by the individual in dentifrices, dental powders, pastes, mouthwashes, nonabrasive gels, chewing gums, topical solutions and the like, e.g., see U.S. Pat. No. 4,205,061. They are designed to be used as prophylactic agents, usually without requiring a prescription or supervision during usage, e.g., see U.S. Pat. No. 4,251,507. Often they are compounded with detergents and other cleaning agents, and this cleaning action is often an important aspect of the invention, e.g., see U.S. Pat. Nos. 4,251,507 and 4,205,061. None of these compounds or compositions are designed to be used as antimicrobial agents for the treatment of periodontitis,

nor are they formulated to be slow release devices for these antimicrobial agents in vivo.

Recent research in periodontal disease (see, for example, *Chemotherapy of Dental Plaque Infections*, *Oral Sci. Rev.* 9:65-107, 1976) indicates that gingivitis and periodontitis are characterized by different types of bacteria. Gingivitis is associated with the accumulation of gram positive cocci and actinomyces, whereas periodontitis is characterized by proportional increases in anaerobic bacteria, such as spirochetes and black pigmented bacteroides (see *Host-Parasite Interactions in Periodontal Disease*. R. J. Genco and S. E. Mergenhagen, eds. Amer. Soc. for Microbiol. Washington, D.C. p. 27-45, 62-75, 1982). The different bacterial compositions of plaque associated with either gingivitis or periodontitis suggest that a mode of treatment that is effective in gingivitis may not be effective in periodontitis. This is an important factor in the present invention, as previous discoveries in the area of periodontal disease have assumed that there is no bacterial specificity in periodontal disease. This is now known to be incorrect. These bacterial differences in plaque may explain why an agent effective in plaque control, such as chlorhexidine, has little effect on gingivitis and no published effect on periodontitis.

Another important finding from recent periodontal research is that the composition of the dental plaque will differ according to its location on the tooth surface. Above the gingival or gum margin, facultative bacteria, such as gram positive cocci and rods, are numerically dominant, whereas below the gum margin, anaerobic motile bacteria such as spirochetes, and anaerobic gram negative rods including the black-pigmented bacteroides are predominant. In other words, two different microbial ecosystems are present on the same tooth surface.

This is illustrated in the accompanying drawings in FIGS. 1a and 1b, which show a cross section of a tooth 10, a periodontal pocket 11, and the gingiva or gum 12. The tooth illustrated in FIG. 1a exhibits periodontal disease in which periodontal attachment of the tooth to the alveolar bone has been destroyed, and a periodontal pocket 11 has been formed between the gum 12 and the root surface of the tooth. Clinical assessment of such deterioration of teeth is made by measuring the depth of the pocket. This is done by inserting a periodontal probe or ruler, a thin metal rod (not shown), to the base of the pocket 14. Two measurements can be obtained with the probe. One, called the pocket depth x, in illustration 1a is the distance between the height of the gingival margin 13 to the base of the pocket 14. The other measurement, y, is the distance between the height of the gingival margin 13 and the cemento-enamel junction (CEJ) 15. The CEJ is extremely valuable because it gives a permanent reference mark on each tooth surface from which one can base further measurements. It enables one to divide the pocket depth measurement into two components: the distance between the CEJ and the top of the gingival margin, y, and the distance between the CEJ and the bottom of the pocket, z. This latter measurement is called the attachment distance. As illustrated in the diseased tooth, the attachment distance is 5 mm and the pocket depth is 8 mm.

FIG. 1b is an enlargement of a section of the type shown in FIG. 1a in which the periodontal pocket 11 is now filled with bacterial plaque. Note that the plaque lies between the tooth and the gingiva in the space

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.